ETF Resumé

BBHTicker Symbol

Vaneck Vectors BioteFund

  • Rising Rates May Hurt Small-Cap Biotech ETF Valuations

    12-23-2016 03:37 PM by Max Chen

    The Federal Reserve has hiked interest rates for the second time in a decade and plans to raise rates three more times next year. With higher interest rates, investors may find small-cap biotechnology exchange traded funds that track companies banking on a breakthrough drug less ...

    Read more

  • 10 Best & Worst ETF Performers of the Day (May 11)

    05-11-2016 05:04 PM by Brenton Garen

    Welcome to the 10 Best & Worst ETF Performers of the Day for Wednesday, May 11, 2016. 10 Best ETF Performers: Sym Name Last Percent Volume UGA US Gasoline 27.57 +5.55% 93,722 SGG DJ-UBS Sugar TR Sub-Idx ETN Ipat...

    Read more

  • Hit The Lab With These 17 Biotech ETFs

    05-02-2016 12:49 PM by Tom Lydon

    The time to buy, regardless of sector, is usually when a particular group falls out of favor, not when it has been bid higher by scores of investors. Some investors view that as the case with the broader healthcare group and biotechnology in particular. Multiple factors, inclu...

    Read more

  • A Cheap ETF Sector Play

    03-21-2016 01:53 PM by Max Chen

    Unloved ETF healthcare segment may provide a cheap opportunity for bargain hunters SPDR S&P 500 ETF (NYSEArca: SPY) is up 0.8% so far this year Investors may also be trying to catch a falling knife after the huge sell-off in the biotech sub-sector as biotechs remain i...

    Read more

  • ETF News and Views

    02-23-2016 04:20 PM by Tom Lydon

    Yorkville ETF Advisers Merges with Van Eck Global Van Eck Global said it is acquiring the Yorkville High Income MLP ETF (NYSEArca: YMLP) and the Yorkville High Income Infrastructure MLP ETF (NYSEArca: YMLI) last year. The reorganization process began late in the third quarter ...

    Read more

  • Disappointing Drug Trials Drag on Biotech ETFs

    01-21-2016 05:00 PM by Tom Lydon

    Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of it...

    Read more

  • ETF Providers Diversifying with Exchange Listings

    01-13-2016 01:05 PM by Tom Lydon

    As exchange traded fund providers look to diversify among primary markets that host their products, NYSE Arca could find greater competition from the Nasdaq and BATS exchanges. The majority of exchange traded products, which include both ETFs and exchange traded notes, are lis...

    Read more

  • ETF Chart of the Day: Hot Biotechnology Sector

    07-30-2015 12:47 PM by Paul Weisbruch, Street One Financial

    This week we have seen decent sized inflows in the largest Biotech Equity based ETP in the U.S. listed landscape, IBB (iShares NASDAQ Biotechnology, Expense Ratio 0.48%), to the tune of about $400 million. Net year to date the fund has reeled in north of $1.2 billion now, push...

    Read more

  • Biotech Hedge Funds are hot, but Biotech ETFs are Hotter

    05-29-2015 02:05 PM by Todd Shriber

    It is no secret that investors love biotechnology stocks and the related exchange traded funds. That love extends to hedge funds, some of which are dedicated healthcare and biotech funds. Hedge funds that focus exclusively on biotech or invest in the space as part of a diversi...

    Read more

  • An ETF for Hedge Funds Favorite Biotechs

    05-27-2015 11:30 AM by Todd Shriber

    It is not a secret that biotechnology stocks are beloved, nor is it a secret that hedge funds are among the investors bestowing some of that love upon the biotech space. "It turns out that there were some interesting positions of hedge funds in biotech, long and short, from th...

    Read more

  • Biotech ETFs are not out for Summer

    05-26-2015 08:00 AM by Todd Shriber

    Rock star and golf aficionado Alice Cooper once told us, as if it was not already apparent, that school is out for summer. Good news for biotechnology bulls: The same cannot be said of some big-name biotech stocks. The "Nasdaq Biotech Index index has outperformed the broader m...

    Read more

  • Biogen Boosts Biotech ETFs to More New Highs

    03-20-2015 11:59 AM by Todd Shriber

    Shares of Biogen Idec (NasdaqGS: BIIB), one of the largest U.S. biotechnology companies, are up 7% Friday and earlier hit an all-time high after the company said an early-stage study revealed its Alzheimers drug, aducanumab, stemmed cognitive decline in patients compared with tho...

    Read more

  • ETFs for the Next Biotech Takeover Targets

    03-10-2015 11:00 AM by Todd Shriber

    On the heels of last weeks news that AbbVie (NYSE: ABBV) will acquire cancer treatments maker Pharmacyclics (NasdaqGS: PCYC) for $21 billion, speculation is abound regarding the next potential takeover targets in the biotechnology industry. The biotech industry and the relevan...

    Read more

  • A Biotech ETF Right for Oncology Mergers and Acquisitions

    03-09-2015 09:30 AM by Todd Shriber

    Last weeks news that AbbVie (NYSE: ABBV) will pay $21 billion, or $261.25 per share in cash and stock, for Pharmacyclics (NasdaqGS: PCYC), a maker of cancer treatments, in what represents the largest takeover of a biotech company in 15 years underscores a couple of points. Fir...

    Read more

  • Healthcare ETFs up at Least 10% This Year

    02-26-2015 05:11 PM by Tom Lydon

    By recent standards, Thursday was a docile day for the health care sector, the second-best performer in the S&P 500 this year behind materials. Just six healthcare exchange traded funds made new highs Thursday compared with 26 the day before. When six of a sectors ETFs rea...

    Read more

  • Healthcare ETFs Have More Room to Run

    02-11-2015 03:38 PM by Tom Lydon

    Healthcare sector exchange traded funds have been outpacing the broader markets and could remain healthy as rising profits diminish concerns over frothy valuations. Over the past year, Health Care Select Sector SPDR (NYSEArca: XLV) rose 25.2% while the SPDR S&P 500 ETF (NY...

    Read more

  • Gilead Could Goose Biotech ETFs

    02-04-2015 07:30 AM by Todd Shriber

    Some well-known biotechnology exchange traded funds could be stirred by Gilead Sciences (NasdaqGS: GILD) fourth-quarter earnings report released Tuesday after the close of U.S. markets. The California-based company posted net income of $3.49 billion, or $2.18 a share, compared...

    Read more

  • Tis the Season for Biotech ETFs

    01-05-2015 08:00 AM by Todd Shriber

    Over the last several years, there has rarely been a bad time to own biotechnology exchange traded funds. That much is confirmed by the presence of multiple biotech ETFs on the annual lists of the top 10 sector funds. In 2014, each of the five major biotech ETFs ranked among t...

    Read more

  • The Dominance of Health Care ETFs in One Chart

    11-20-2014 09:30 AM by Todd Shriber

    Stellar performances by health care stocks and exchange traded funds this year have been well-document and plenty of investors know that the Health Care Select Sector SPDR (NYSEArca: XLV) is the best of the nine sector SPDR ETFs to this point in the year. Up 24.7% year-to-date...

    Read more

  • Biotech ETFs Prescribe New ETFs

    10-23-2014 11:49 AM by Todd Shriber

    U.S. stocks appear headed for a fifth consecutive day of gains. While that is good news, the S&P 500s recent winning streak serves as a reminder regarding why October is, historically, the most volatile month of the year. Despite that volatility, biotechnology exchange tra...

    Read more

  • Biotech ETFs Arent Waving the White FlagYet

    10-15-2014 08:00 AM by Tom Lydon

    One of this years sharpest pullbacks in equities was, some market observers would say, attributable to the late first-quarter/early second-quarter retrenchment in biotechnology stocks and the corresponding exchange traded funds. So severe was the aforementioned selloff in biot...

    Read more

  • Biotech ETFs Look to Build on Hot August Returns

    09-03-2014 11:00 AM by Tom Lydon

    It was a frequent event in the month of August. Throughout the month, daily checks of exchange traded funds making new all-time highs turned up plenty of health care funds. Much to the chagrin of the biotechnology bears that growled so loud late in the first quarter and early ...

    Read more

  • So Much for That Biotech ETF Bubble

    08-20-2014 12:28 PM by Todd Shriber

    It seems like only yesterday that there was a cacophony of criticism and doubt from naysayers regarding biotechnology stock and exchange traded funds. In reality, yesterday was the first quarter when the usually pricey biotech sector soared to valuations that were double its a...

    Read more

  • Most Searched ETFs: Tactical Time

    06-28-2014 08:00 AM by Todd Shriber

    In a lethargic week for U.S. stocks, investors were seen taking a tactical approach to exchange traded funds. At least that is the anecdotal evidence provided by our weekly look at the most searched ETFs. While broad market ETFs and dividend funds usually occupy several spots ...

    Read more

  • Vertex Lifts These Biotech ETFs

    06-24-2014 11:36 AM by Todd Shriber

    Shares of Vertex Pharmaceuticals (NasdaqGS: VRTX) surged more than 42% Tuesday on volume that is already 11 times above the daily average after the company said two Phase III trials for its cystic fibrosis treatment showed encouraging results. Analysts doubted the ability of V...

    Read more

  • More Upside Possible for Biotech ETF

    05-06-2014 12:46 PM by Todd Shriber

    From its Feb. 25 to its April 14 lows, the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) tumbled 21.2%. That fits the definition of a bear market and IBBs decline, along those of the other biotech ETFs, received ample attention due in large part to talk that the biotech sec...

    Read more

  • Biotech ETFs in Bear Market, Plunge Below Key Trendlines

    04-15-2014 02:36 PM by Tom Lydon

    Biotechnology sector exchange traded funds are caught in one of their worst sell-offs, breaking below their long-term trendlines and hovering in bear market territory, as investors dump growth stocks. The largest biotechnology-related ETF, the iShares Nasdaq Biotechnology ETF ...

    Read more

  • Investors Say Bye-Bye to Biotech ETFs

    04-08-2014 12:45 PM by Todd Shriber

    It has been said, and it is more often than not true, that flows data for exchange data is not a predictor of future performance, but rather a sign of investors chasing past performance. When it comes to once beloved biotechnology ETFs, it is not debatable that the groups rece...

    Read more

  • ETF Performance Report: March & Q1

    03-31-2014 02:55 PM by Max Chen

    Concern over a global market slowdown and geopolitical risks kept equities markets and stock exchange traded funds relatively unchanged since the start of the year, but the S&P 500 Index is still heading toward its fifth quarterly gain, albeit a small one. The Dow Jones In...

    Read more

  • Overlooked Bearish Biotech ETF Grows UpSort Of

    03-21-2014 12:06 PM by Todd Shriber

    An oft-discussed theme over the past month has been the decline of biotechnology stocks and exchange traded funds, a conversation that is gaining steam Friday as the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB), the largest biotech ETF, drifts below its 50-day moving average....

    Read more

  • Why This Biotech ETF Leads the Pack

    02-21-2014 08:15 AM by Todd Shriber

    There are five biotechnology exchange traded funds on the market today. Confirming just how strong the sub-sector has been this year three of those ETFs the First Trust NYSE Arca Biotechnology Index Fund (NYSEArca: FBT), the Market Vectors Biotech (NYSEArca: BBH) and the iShares...

    Read more

  • The One ETF Really Benefiting From the Intercept Pharma News

    01-09-2014 01:57 PM by Todd Shriber

    No need to do a double take with the following because it is true: Shares of Intercept Pharmaceuticals (NasdaqGM: ICPT) are up $210, or a tidy 290%, after trials for the companys liver disease treatment proved successful. That is good news for the biotechnology sector, which i...

    Read more

  • Most Popular Tickers on ETF Trends Week of Dec. 27

    12-28-2013 08:00 AM by Todd Shriber

    Stocks closed flat on Friday, but overall, it was a decent holiday-shortened week for U.S. equities as the S&P 500 managed to tack on almost 0.8% in just 3.5 trading days. While some traders and investors were busy pondering the fate of Twitter (NYSE: TWTR), among other ma...

    Read more

  • Intense Duel to be 2013s Best Health Care ETF

    12-23-2013 08:00 AM by Tom Lydon

    This has been, quite simply a very, very good year in which to be long health care exchange traded funds. The Health Care Select Sector SPDR (NYSEArca: XLV) is battling with its discretionary rival to be the best of the nine SPDR ETFs for 2013 and XLV spent some time as the th...

    Read more

  • Solar ETFs Look for 2014 Sequel

    12-19-2013 07:30 AM by Todd Shriber

    After several years of struggling and reverse splits in 2012, solar exchange traded funds bounced back with a vengeance in 2013. With the year almost over, the Guggenheim Solar ETF (NYSEArca: TAN) ranks as the years top-performing non-leveraged ETF, having more than doubled. T...

    Read more

  • 5 ETF Outperformers May Still Have Legs

    12-17-2013 02:14 PM by Max Chen

    The best performing exchange traded funds this year include some surprise moves and others adding on another stellar year. ETFs that track the solar, alternative energy, broker dealer and biotechnology sectors have outperformed this year, writes Trang Ho for Investor's Busines...

    Read more

  • The Emergency Room ETF Could Soar Again in 2014

    12-17-2013 08:45 AM by Tom Lydon

    There is no denying 2013 will go down as a banner year for exchange traded funds with ties to the health care sector. Whether it has been broader plays on the sector such as the Health Care Select Sector SPDR Fund (NYSEArca: XLV) or more focused sub-industry plays like the Mar...

    Read more

  • Some of 2012s Best Sector ETFs Kept Soaring in 2013

    12-10-2013 07:30 AM by Tom Lydon

    There are various theories regarding buying a previous years laggards with the expectation that the new year will bring better results. Call it the trash to treasure theory. As is the case with all market theories, last years rubbish turning to this years gold is not 100% fool...

    Read more

  • Biotech ETFs: More Tricks Than Treats in October

    10-31-2013 02:45 PM by Max Chen

    Biotech exchange traded funds, market leaders for much of this year, stumbled in October as the government shutdown had an unexpectedly debilitating affect on the high-flying sub-industry. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks large biotech or phar...

    Read more

  • Biotech ETFs Look to Claw Back After Shutdown Slump

    10-22-2013 02:24 PM by Todd Shriber

    For most of this year biotechnology exchange traded funds have been among the most beloved and top-performing sector ETFs. The recent U.S. government shutdown led to some unexpected retrenchment in a sector previously hailed for proving impervious to macro shocks. While past p...

    Read more

  • Triple-Digit Divas Reside in These ETFs

    10-18-2013 11:37 AM by Todd Shriber

    Or, in the case of Google (NasdaqGM: GOOG), a quadruple-digit diva. The Internet search giant made it to $1,000, or roughly double the share price of rival Apple (NasdaqGM: AAPL), on the back of a strong third-quarter earnings report. Trading at or around $1,000 is a nice feat...

    Read more

  • Sell-Off in Biotech ETFs Could Be a Temporary Setback

    10-10-2013 07:30 AM by Tom Lydon

    Biotechnology exchange traded funds are on a three-day sell-off after falling short of its 52-week high Friday, but the sector can still find its footing. The he iShares Nasdaq Biotech (NasdaqGM: IBB) has declined 7.5% in the past three sessions, Market Vectors Biotech ETF (NY...

    Read more

  • 10 ETF Investments That Got the Most Bang for Your Buck

    10-08-2013 01:14 PM by Tom Lydon

    Riding out tax hikes, interest rate risk and geopolitical tensions, the broad equity markets touched historic highs this year, with alternative energy, biotech and technology stock exchange traded funds leading the pack. In the technology space, social media stocks are experie...

    Read more

  • ETF Categories That Just Keep On Winning

    10-02-2013 03:00 PM by Gary Gordon

    Stocks as an asset class have shrugged off a wide variety of risks throughout the year. Sequestration failed to derail equity enthusiasm. The May-June interest rate spike did little to deter dip-buyers. And I suspect that any actual downside for the markets in October, whether ca...

    Read more

  • Three ETFs to Play the Outperforming Biotech Sector

    08-19-2013 04:39 PM by Tom Lydon

    The biotechnology sector has been one of the best performing areas in the market this year. While investors can try to bet big, and potentially lose big, on biotech stocks, an exchange traded fund helps diversify risk with a basket of securities. "The jarring pace of change, s...

    Read more

  • Investors Clamor for Generic Drug ETF

    05-06-2013 04:20 PM by Tom Lydon

    Big pharma will soon lose patents on blockbuster drugs, boosting the market for cheap generic drug producers. Too bad there isn't an exchange traded fund that tracks global generic drug makers. The cheap generic drug market could account for $29 billion in total revenue as abo...

    Read more

  • Ups and Downs for ETFs in 2012

    12-31-2012 01:32 PM by Tom Lydon

    The end of 2012 is here and certain exchange traded funds will close out the year with a bang, while others have hit the market with a thud. Homebuilders rebounded in 2012 beautifully, while commodities just plain underperformed. "This year has proven to be a rather successful...

    Read more

  • Why Biotech ETFs are a Top Sector in 2012

    12-19-2012 10:00 AM by Tom Lydon

    Biotechnology exchange traded funds have reaped the performance benefits of merger and acquisition activity and the so-called patent cliff. This sector has produced some of the best-performing ETFs in 2012. "The past few years were particularly tough for small- and mid-cap bio...

    Read more

  • More M&A Deals Could Boost Biotech ETFs

    12-11-2012 03:30 PM by Tom Lydon

    As drug providers shift away from blockbuster drugs, the biotechnology sector, along with related exchange traded funds, will be supported by the next wave of specialized or targeted drugs. For instance, Amgen (NasdaqGS: AMGN) this week announced a deal to acquire genetic sequ...

    Read more

  • Biotech ETFs Holding Up During Rocky November

    11-19-2012 03:20 PM by Tom Lydon

    Investors got a much-deserved relief rally Monday on hopes the Obama administration and Congress will be able to hammer out a deal to avoid the fiscal cliff before the deadline. In November, the equities market has been weakening as investors pulled out of stocks ahead of the ...

    Read more

  • Biotech ETFs Cool After Strong Run

    08-13-2012 08:53 AM by Tom Lydon

    An exchange traded fund indexed to biotechnology stocks has pulled back about 10% from its all-time reached last month as the sector cools after leading the market higher through much of 2012. Biotech ETFs have been successful in 2012, with some funds returning more than 30% y...

    Read more

  • Biotech ETFs Weather Market Storm

    05-14-2012 10:20 AM by John Spence

    One sector that has held up very well amid weakness in the overall market is biotech. In fact, ETFs tracking the biotech stocks remain near all-time highs on successful drug trial tests and some investors positioning for deals in the sector. The iShares Nasdaq Biotechnology (N...

    Read more

  • Natural Gas ETF Rebound Continues with 9% Weekly Advance

    05-12-2012 08:45 AM by Tom Lydon

    The largest exchange traded fund following natural gas futures was the top gainer in ETFs this week with a 9% rally, stirring hopes that the recovery in natural gas prices is real. Natural Gas. The U.S. Energy Information Administration revealed a smaller-than-expected increas...

    Read more

  • Choosing the Right Biotech ETF Exposure

    04-20-2012 03:09 PM by Tom Lydon

    Coming off the hopeful drug trial tests and lucrative takeover bids, the biotech sector and related exchange traded funds that follow the industry surged this week. However, some biotechnology ETFs are doing better than the others. The large biotech firms are flush with cash a...

    Read more

  • Biotech ETFs Break Out

    01-19-2012 09:45 AM by John Spence

    The rally in biotechnology exchange traded funds is going vertical in early 2012 with the sector's largest ETF posting a gain of 20% over the past three months. The $1.5 billion iShares Nasdaq Biotechnology Index Fund (IBB) is breaking out to new all-time highs. The ETF is up ...

    Read more

  • Six HOLDRS Become Van Eck ETFs

    12-21-2011 07:16 AM by Tom Lydon

    Six Merrill Lynch HOLDRS exchange traded securities stopped trading as planned on Tuesday. The funds were officially transferred and changed into Van Eck Global exchange traded funds, and the new funds will begin trading Wednesday. Trading in the biotech, banking, oil services...

    Read more

  • HOLDRS Making Transition to Market Vector ETFs

    11-23-2011 02:44 PM by Tom Lydon

    Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch reached an accord on six HOLDRs in August, and now, the transition from the Merrill Lynch HOLDRs to Market Vector exchange traded funds is underway. An exchange offer for the HOLDRS commenced on Nov. 11 an...

    Read more

  • Van Eck, Merrill Lynch in Agreement Over HOLDRS

    08-15-2011 08:26 AM by Tom Lydon

    Van Eck Global and Bank of America (NYSE: BAC) subsidiary Merrill Lynch have reached a deal in which Van Eck plans to offer investors in six HOLDRS the chance to swap for shares of new exchange traded funds. Van Eck filed for six sector-specific ETFs with the Securities an...

    Read more

  • Biotech ETFs Mixed After Gilead Subpoena

    06-13-2011 01:53 PM by Tom Lydon

    Biotechnology exchange traded funds were mixed Monday after sector bellwether Gilead Sciences (NasdaqGS: GILD) disclosed it has received a subpoena from the U.S. Department of Justice. Gilead shares were down nearly 1% but pared their earlier loss after the company late Friday...

    Read more

  • Biogen Earnings, Drug Data to Lift Biotech ETFs

    04-21-2011 05:55 AM by John Spence

    Biogen (NasdaqGS: BIIB) shares jumped more than 20% in premarket action Thursday after the company reported higher-first quarter profit and released encouraging data on an experimental multiple sclerosis drug. The data on the drug, BG-12, was very competitive versus other appr...

    Read more

  • 5 Biotechnology ETFs to Play Innovation

    02-22-2011 02:00 PM by Tom Lydon

    While the broader market has picked up its pace, the biotechnology sector has not seen a similar surge in performance. Still, investors should keep in mind the various biotech exchange traded fund (ETF) plays to stay positioned for a resurgence in the sector. Currently, the bi...

    Read more

  • Play the Booming Biotech Sector With ETFs

    12-21-2010 03:00 PM by Tom Lydon

    Economic downturn? What economic downturn? Despite lackluster economic growth, biotechnology exchange traded funds (ETFs) have managed to notch solid performance this year. In the United Kingdom alone, the bioscience sector has exploded. It now includes 942 companies, with 345...

    Read more

  • Biotech ETFs: 5 Ways to Play Innovation

    08-08-2010 01:00 PM by Tom Lydon

    Biotechnology has been improving our quality of life for generations. The industry does everything from researching a cure for cancer to finding disease-resistant crops and more. While this can be a difficult sector in which to invest, there are five exchange traded funds (ETFs) ...

    Read more

  • 5 Biotech ETFs If You're Bullish

    06-25-2010 01:00 AM by Tom Lydon

    Biotechnology has helped improve the lives of many people. Naturally, many biotech stocks boom or bust based on the success of products in their pipeline. But if youre looking for a more diversified and steady approach to biotech investing, look no further than exchange traded fu...

    Read more

  • Why Biotech ETFs May Be the Better Choice

    06-17-2009 11:00 AM by Tom Lydon

    Biotechnology stocks present opportunities, but given the unique challenges of the sector, exchange traded funds (ETFs) may be the better route to go if you're considering making an investment. Owning individual biotechnology companies can be a challenging way to invest in th...

    Read more

  • How Biotech ETFs Can Rise Above Challenges

    05-12-2009 06:00 AM by Tom Lydon

    In the current economic atmosphere, the biotechnology industry and related exchange traded funds (ETFs) are feeling stressed as investment pullbacks have impeded the sector. Ernst & Young posted their annual report, which stated that the recession could force companies to ...

    Read more

  • How Biotech ETFs Are Overcoming Sector's Trials

    03-24-2009 11:00 AM by Tom Lydon

    The biotechnology sector is a place of risky ventures that at times produce lucrative innovations, but the sector and related exchange traded funds (ETFs) need a helping hand in difficult times. Small biotech companies are courting potential buyers, but not many are large enou...

    Read more

  • Midday Market Update: Downgrades and Mergers Lead Markets and ETFs

    03-12-2009 10:00 AM by Tom Lydon

    General Electric (GE) has been stripped of their AAA credit rating by Standard & Poor's, citing troubles within inner-workings,. but exchange traded funds (ETFs) and market are rising above it so far. GE was cited for the poor performance of their finance unit, however, s...

    Read more

  • What Stem Cell Research Means for Biotech ETFs

    03-10-2009 12:00 PM by Tom Lydon

    Will President Barack Obama's decision to lift restrictions on stem cell research be beneficial to the biotechnology industry and its exchange traded funds (ETFs)? This lift on research restrictions will once again allow researchers to use federal funds to work with new cell li...

    Read more

  • How Obama's Health Care Reform Impacts Biotech ETFs

    03-05-2009 12:00 PM by Tom Lydon

    President Barack Obama's proposal for health care reform has the biotechnology industry and related exchange traded funds (ETFs) quaking in their boots. Why? This was the industry that seemed relatively immune to the stock markets demise. However, many believe that the Presiden...

    Read more

  • Midday Market Update: Can New Program Spark an ETF Rally?

    03-03-2009 10:00 AM by Tom Lydon

    Consumers and small businesses may finally get the loans they need, as the Federal Reserve is launching its much awaited $200 billion consumer credit program, although markets and exchange traded funds (ETFs) may need more than that for a sustained rally. TALF. Autos, educati...

    Read more

  • Health Care ETFs' $140 Billion Boost

    02-19-2009 06:00 AM by Tom Lydon

    When President Barack Obama put his John Hancock on the $787 billion stimulus package, $140 billion of it was related specifically to fixing health care and, in turn, related exchange traded funds (ETFs). What's in the bill? A provision to help workers who lose their j...

    Read more

  • Why Biotech, ETFs Want Piece of Bailout

    12-11-2008 06:00 AM by Tom Lydon

    The ailing economy and credit crisis has taken its toll on the biotechnology industry hurting its stocks and exchange traded funds (ETFs). In an attempt to grab a piece of the pie, the sector is seeking aid from the federal government. On Wednesday,biotech executivesplans to ...

    Read more

  • Biotech ETFs Stay Healthy Despite Market Ills

    10-22-2008 06:00 AM by Tom Lydon

    Biotechnology, while hurting along with the rest of the market, is one of the few that can boast market outperformance during these tough market times, evidenced in the performance of the related exchange traded funds (ETFs). Billy Fisher for TheStreet points out that while th...

    Read more

  • ETF Selecting Doesn't Have To Be Like A Box Of Chocolates

    09-03-2008 01:00 AM by Tom Lydon

    When it comes to selecting your exchange traded fund (ETF), it doesn't have to be like a box of chocolates. Unlike Forrest Gump, investors do not have to choose an ETF and never know what they are going to get... at least savvy ones don't. Certain ETFs just do not live up t...

    Read more

  • Biotechnology ETFs Growing...Like Genetically Modified Crops?

    07-16-2008 11:00 AM by Tom Lydon

    Biotechnology is the non-commodity exchange traded fund (ETF) area du jour, it seems. In a time where the markets seem bleak, the sector is delivering a ray of light. Genentech (DNA) this week upped its 2008 forecast, and also said its second-quarter profit rose 4.7%, thanks t...

    Read more

  • Can Biotech And Agriculture ETFs Get Acreage With Your Money?

    07-10-2008 11:00 AM by Tom Lydon

    Not many exchange traded funds (ETFs) outside those focused on commodities are perched above their 200-day moving averages. That makes it worth noting that two biotechnology ETFs crossed the mark recently. Both iShares Nasdaq Biotechnology (IBB) and Biotechnology HOLDRs (BBH) ...

    Read more